GlassScriptPhysician profile
Roberto Gomez
NPI 1609529700
$1,681.16
in general payments reported to CMS, 2019-2025
14 companies · $406 in 2025
The $406 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $55.47 · 2023: $410 · 2024: $810 · 2025: $406.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,626.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,625.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $424.86 | 2023-2025 | Verquvo, Capvaxive |
| Novartis Pharmaceuticals Corporation | $377.27 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $143.41 | 2024-2025 | Eliquis, Camzyos |
| Boston Scientific Corporation | $107.24 | 2024-2025 | Lux-Dx Insertable Cardiac Monitor, Accolade Sr |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $104.40 | 2024-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $85.62 | 2023 | Jardiance |
| Philips North America LLC | $84.82 | 2025 | Mechanical Tools, Mcot |
| Amgen INC. | $83.67 | 2023-2024 | Repatha |
| Janssen Pharmaceuticals, INC | $76.36 | 2023-2024 | Xarelto |
| Pfizer INC. | $61.29 | 2023-2024 | |
| Glaxosmithkline, LLC. | $55.47 | 2022 | |
| Medtronic, INC. | $37.00 | 2023-2024 | Linq II, Mycarelink |
| Novo Nordisk INC | $25.64 | 2024 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $14.11 | 2024 | Farxiga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roberto Gomez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.